诊断学理论与实践 ›› 2019, Vol. 18 ›› Issue (06): 605-712.doi: 10.16150/j.1671-2870.2019.06.001
• 专家论坛 • 下一篇
收稿日期:
2019-12-03
出版日期:
2019-12-25
发布日期:
2019-12-25
通讯作者:
蒋荣珍
E-mail:jianrzh@163.com
基金资助:
Received:
2019-12-03
Online:
2019-12-25
Published:
2019-12-25
中图分类号:
蒋荣珍, 钱智敏. 子痫前期的预测、预防研究现状及进展[J]. 诊断学理论与实践, 2019, 18(06): 605-712.
[1] |
Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis[J]. BJOG, 2012, 119(7):778-787.
doi: 10.1111/j.1471-0528.2012.03311.x URL |
[2] |
Hertig A, Berkane N, Lefevre G, et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia[J]. Clin Chem, 2004, 50(9):1702-1703.
doi: 10.1373/clinchem.2004.036715 URL |
[3] |
Okwudire EG, Atalabi OM, Ezenwugo UM. The use of uterine artery doppler indices for prediction of pre-eclampsia in Port-Harcourt, Nigeria[J]. Niger Postgrad Med J, 2019, 26(4):223-229.
doi: 10.4103/npmj.npmj_54_19 URL |
[4] | National Collaborating Centre for Women's and Children's Health (UK). Hypertension in pregnancy: The management of hypertensive disorders during pregnancy[M]. London: RCOG Press, 2010. |
[5] | ACOG Committee Opinion No. 743: Low-dose aspirin use during pregnancy[J]. Obstet Gynecol, 2018, 132(1):e44-e52. |
[6] | Chaemsaithong P, Pooh RK, Zheng M, et al. Prospective evaluation of screening performance of first-trimester prediction models for preterm preeclampsia in an Asian population[J]. Am J Obstet Gynecol, 2019, 221(6):650. |
[7] |
O'Gorman N, Wright D, Poon LC, et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations[J]. Ultrasound Obstet Gynecol, 2017, 49(6):756-760.
doi: 10.1002/uog.17455 pmid: 28295782 |
[8] |
Akolekar R, Syngelaki A, Poon L, et al. Competing risks model in early screening for preeclampsia by biophysical and biochemical markers[J]. Fetal Diagn Ther, 2013, 33(1):8-15.
doi: 10.1159/000341264 pmid: 22906914 |
[9] |
Tan MY, Wright D, Syngelaki A, et al. Comparison of dia-gnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE[J]. Ultrasound Obstet Gynecol, 2018, 51(6):743-750.
doi: 10.1002/uog.19039 pmid: 29536574 |
[10] | Sonek J, Krantz D, Carmichael J, et al. First-trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volu-me[J]. Am J Obstet Gynecol, 2018, 218(1):126. |
[11] |
Park FJ, Leung CH, Poon LC, et al. Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy[J]. Aust N Z J Obstet Gynaecol, 2013, 53(6):532-539.
doi: 10.1111/ajo.12126 URL |
[12] | O'Gorman N, Wright D, Syngelaki A, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation[J]. Am J Obstet Gynecol, 2016, 214(1):103. |
[13] |
Krantz DA, Hallahan TW. Incorporating the probability of competing event(s) into the preeclampsia competing risk algorithm[J]. Am J Obstet Gynecol, 2019, 221(5):533-534.
doi: S0002-9378(19)30901-9 pmid: 31306651 |
[14] |
Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia[J]. N Engl J Med, 2017, 377(7):613-622.
doi: 10.1056/NEJMoa1704559 URL |
[15] |
Tenório MB, Ferreira RC, Moura FA, et al. Oral antioxidant therapy for prevention and treatment of preeclampsia: Meta-analysis of randomized controlled trials[J]. Nutr Metab Cardiovasc Dis, 2018, 28(9):865-876.
doi: S0939-4753(18)30190-X pmid: 30111493 |
[16] | Committee on Practice Bulletins—Obstetrics. American College of Obstetricians and Gynecologists′ Committee on Practice Bulletins ACOG Practice Bulletin No. 202: Gestational hypertension and preeclampsia[J]. Obstet Gynecol, 2019, 133(1):e1-e25. |
[17] |
Brown MA, Magee LA, Kenny LC, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice[J]. Pregnancy Hypertens, 2018, 13:291-310.
doi: S2210-7789(18)30126-0 pmid: 29803330 |
[18] | Jiang R, Teng Y, Huang Y, et al. Preeclampsia serum-induced collagen I expression and intracellular calcium levels in arterial smooth muscle cells are mediated by the PLC-γ1 pathway[J]. Exp Mol Med, 2014, 46:e115. |
[19] |
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)[J]. J Thromb Haemost, 2006, 4(2):295-306.
pmid: 16420554 |
[20] |
Hybiak J, Broniarek I, Kiryczyński G, et al. Aspirin and its pleiotropic application[J]. Eur J Pharmacol, 2020, 866:172762.
doi: 10.1016/j.ejphar.2019.172762 URL |
[21] |
Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis[J]. Am J Obstet Gynecol, 2018, 218(3):287-293.
doi: 10.1016/j.ajog.2017.11.561 URL |
[22] | 中国高血压防治指南修订委员会, 高血压联盟中国, 中华医学会心血管病学分会, 等.中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1):24-56. |
[23] |
Spracklen CN, Smith CJ, Saftlas AF, et al. Maternal hyperlipidemia and the risk of preeclampsia: a meta-analysis[J]. Am J Epidemiol, 2014, 180(4):346-358.
doi: 10.1093/aje/kwu145 URL |
[24] |
Montoro MN, Kjos SL, Chandler M, et al. Insulin resistance and preeclampsia in gestationaldiabetes mellitus[J]. Diabetes Care, 2005, 28(8):1995-2000.
pmid: 16043744 |
[25] |
Jin WY, Lin SL, Hou RL, et al. Associations between maternal lipid profile and pregnancy complications and perinatal outcomes: a population-based study from China[J]. BMC Pregnancy Childbirth, 2016, 16:60.
doi: 10.1186/s12884-016-0852-9 URL |
[26] | 郭晓蒙, 张烨, 王娟, 等. BMI联合血脂对妊娠期高血压及子痫前期的预测价值[J]. 中国妇产科临床杂志, 2019, 20(3):199-201. |
[27] |
Siddiqui F, Kurbasic A, Lindblad U, et al. Effects of a culturally adapted lifestyle intervention on cardio-metabolic outcomes: a randomized controlled trial in Iraqi immigrants to Sweden at high risk for Type 2 diabetes[J]. Metabolism, 2017, 66:1-13.
doi: 10.1016/j.metabol.2016.10.001 URL |
[28] | Assaf-Balut C, García de la Torre N, Fuentes M, et al. A high adherence to six food targets of the mediterranean diet in the late first trimester is associated with a reduction in the risk of materno-foetal Outcomes: The st. carlos gestational diabetes mellitus prevention study[J]. Nutrients, 2018, 11(1) pii: E66. |
[29] |
Muñó z Muñóz A, Gómez-Cantarino S, de Dios Aguado MLM, et al. Nutritional habits and levels of physical activity during pregnancy, birth and the postpartum period of women in Toledo (Spain): study protocol for a two-year prospective cohort study (the PrePaN study)[J]. BMJ Open, 2019, 9(7):e029487.
doi: 10.1136/bmjopen-2019-029487 URL |
[30] | LeFevre N, Krumm E. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy[J]. Am Fam Physician, 2019, 100(7):403-405. |
[31] | Abalos E, Duley L, Steyn DW, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy[J]. Cochrane Database Syst Rev, 2018, 10:CD002252. |
[32] |
Pels A, Mol BWJ, Singer J, et al. Influence of gestational age at initiation of antihypertensive therapy: secondary analysis of CHIPS trial data (Control of Hypertension in Pregnancy Study)[J]. Hypertension, 2018, 71(6):1170-1177.
doi: 10.1161/HYPERTENSIONAHA.117.10689 URL |
[33] |
Panaitescu AM, Roberge S, Nicolaides KH. Chronic hypertension: effect of blood pressure control on pregnancy outcome[J]. J Matern Fetal Neonatal Med, 2019, 32(5):857-863.
doi: 10.1080/14767058.2017.1390742 pmid: 28994336 |
[34] | Magee LA, Singer J, von Dadelszen P, et al. Less-tight versus tight control of hypertension in pregnancy[J]. N Engl J Med, 2015, 372(24):2367-2368. |
[35] | Webster K, Fishburn S, Maresh M, et al. Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance[J]. BMJ, 2019, 366:l5119. |
[36] | Yokoyama K, Takahashi N, Yada Y, et al. Prolonged maternal magnesium administration and bone metabolism in neonates[J]. Early Hum Dev, 2010, 86:18 |
[37] |
Altman D, Carroli G, Duley L, et al. Do women with pre- eclampsia, their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placeb o-controlled trial[J]. Lancet, 2002, 359(9321):1877-1890.
doi: 10.1016/S0140-6736(02)08778-0 URL |
[38] |
Belfort MA, Anthony J, Saade GR, et al. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia[J]. N Engl J Med 2003; 348:304-11.
doi: 10.1056/NEJMoa021180 URL |
[39] |
Trapani A Jr, Gonçalves LF, Trapani TF, et al. Perinatal and hemodynamic evaluation of sildenafil citrate for preeclampsia treatment: A randomized controlled trial[J]. Obstet Gynecol, 2016, 128(2):253-259.
doi: 10.1097/AOG.0000000000001518 URL |
[40] |
Vilchez G, Dai J, Lagos M, et al. Maternal side effects & fetal neuroprotection according to body mass index after magnesium sulfate in a multicenter randomized controlled trial[J]. J Matern Fetal Neonatal Med, 2018, 31(2):178-183.
doi: 10.1080/14767058.2017.1279143 URL |
[41] | Duley L, Gülmezoglu AM, Henderson-Smart DJ, et al. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia[J]. Cochrane Database Syst Rev, 2010, 10(11): CD000025. |
[42] |
Belfort MA, Anthony J, Saade GR, et al. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia[J]. N Engl J Med, 2003, 348:304-311.
doi: 10.1056/NEJMoa021180 URL |
[43] |
Vigil-de Gracia P, Ramirez R, Durán Y, et al. Magnesium sulfate for 6 vs 24 hours post delivery in patients who received magnesium sulfate for less than 8 hours before birth: a randomized clinical trial[J]. BMC Pregnancy Childbirth, 2017, 17(1):241.
doi: 10.1186/s12884-017-1424-3 URL |
[44] |
Vigil-de Gracia P, Ludmir J, Ng J, et al. Is there benefit to continue magnesium sulphate postpartum in women receiving magnesium sulphate before delivery? A randomised controlled study[J]. BJOG, 2018, 125(10):1304-1311.
doi: 10.1111/1471-0528.15320 URL |
[45] |
Easterling T, Hebert M, Bracken H, et al. A randomized trial comparing the pharmacology of magnesium sulfate when used to treat severe preeclampsia with serial intravenous boluses versus a continuous intravenous infusion[J]. BMC Pregnancy Childbirth, 2018, 18(1):290.
doi: 10.1186/s12884-018-1919-6 URL |
[46] | Pascoal ACF, Katz L, Pinto MH, et al. Serum magnesium levels during magnesium sulfate infusion at 1 gram/hour versus 2 grams/hour as a maintenance dose to prevent eclampsia in women with severe preeclampsia: A randomized clinical trial[J]. Medicine, 2019, 98(32):e16779. |
[1] | 张祎博, 吴文娟, 毕宇芳, 景峰, 顾志冬, 杨之涛, 尚寒冰, 林靖生, 陈尔真. 大型方舱医院感染预防与控制体系的建设和实践探索[J]. 诊断学理论与实践, 2022, 21(02): 165-168. |
[2] | 庄蕾, 高卫益. 新型冠状病毒肺炎疫情期间非定点医疗机构“分区管理”策略[J]. 诊断学理论与实践, 2022, 21(02): 245-247. |
[3] | 王亦晨, 周剑平, 杨振华, 王敏慧, 刘佳, 倪语星, 张祎博, 石大可, 徐玉敏. 新型冠状病毒肺炎救治临时定点医院工作人员医院感染防控管理方案[J]. 诊断学理论与实践, 2022, 21(02): 270-272. |
[4] | 上海交通大学医学院附属瑞金医院肺小结节诊治和管理学科群专家组. 肺结节活检术风险管理瑞金专家共识[J]. 诊断学理论与实践, 2022, 21(01): 22-31. |
[5] | 付朝伟. 阿尔茨海默病重在预防——《中国阿尔茨海默病报告2021》解读[J]. 诊断学理论与实践, 2022, 21(01): 8-11. |
[6] | 杨晓辰, 朱圆, 孙琼, 余小萍, 张娴. 主观认知下降的影响因素、评估与干预研究新进展[J]. 诊断学理论与实践, 2022, 21(01): 90-94. |
[7] | 陈曦, 杜鹃. 多发性骨髓瘤预后风险的精准评估[J]. 诊断学理论与实践, 2021, 20(06): 522-528. |
[8] | 李海. 慢加急肝衰竭的诊断标准及管理[J]. 诊断学理论与实践, 2021, 20(05): 434-438. |
[9] | 叶晨静, 张弦, 周淑颖, 张晨莉, 龚艳春, 童建菁, 阎骅. 操作技能直接观察评估考核在全科住院医师规范化培训中的应用及效果评价[J]. 诊断学理论与实践, 2021, 20(03): 311-313. |
[10] | 陈信光, 张凤祥. 特定人群室性心律失常风险评估进展及策略[J]. 诊断学理论与实践, 2020, 19(06): 549-554. |
[11] | 刘彤, 王鑫. 心房颤动预后不良风险的评估策略[J]. 诊断学理论与实践, 2020, 19(06): 555-558. |
[12] | 徐琛莹, 许庆玲, 唐陈月, 俞丽芬. 上海40~59岁无症状人群结肠直肠腺瘤的检出率及其与胃息肉检出的关系[J]. 诊断学理论与实践, 2020, 19(05): 504-509. |
[13] | 游利. 重视骨转换指标的临床应用及评估[J]. 诊断学理论与实践, 2020, 19(03): 214-218. |
[14] | 丁凤鸣, 周妍, 田雪, 廖若敏, 张杏怡. 胜任力模型在呼吸与危重症医学科进修医师培训中的应用[J]. 诊断学理论与实践, 2020, 19(02): 203-205. |
[15] | 马文明, 李强, 卓然, 冒永鑫, 戴军, 罗艳, 孙福康. 嗜铬细胞瘤术前CT影像学参数与围手术期参数的相关性研究[J]. 诊断学理论与实践, 2020, 19(02): 172-176. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||